Latest: FDA Approves New Biosimilar for Oncology Treatment

Recent Research and Future Directions in IDH-Mutant Gliomas

0 Mins
Panelists discuss how voracidinib shows superior brain penetration compared to other IDH inhibitors and explore exciting combination approaches with immunotherapy and vaccines that target the immunosuppressive effects of 2-HG in the tumor microenvironment.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago